Hemophilia Therapeutics Market Examined & Forecast by GlobalData in Its Topical Research Study Available at MarketPublishers.com
12 Oct 2017 • by Natalie Aster
LONDON - Hemophilia A and B are recognised as rare recessive X-linked genetic deficiencies in the blood clotting factors VIII and IX, respectively, that are characterised by the failure of blood to create normal clots after any damage to veins and/or tissues.
Today, across the 7 major markets for hemophilia patients suffering from severe forms of this disease are usually treated on a prophylactic basis rather than on-demand after bleeds.
Traditionally, the world’s hemophilia market was led by short-acting rFVIII or FIX concentrates. But, over the past few years the competition in this market has intensified considerably with approval of extended half-life products that are able to reduce the burden associated with prophylaxis. However, these improvements have brought benefits mainly for hemophilia B patients, whilst substantial unmet need remain for hemophilia A patients and also for patients with inhibitors, who don’t respond to standard treatments.
At present, activity in the hemophilia pipeline is strong. There are two candidates, Alnylam’s fitusiran and Roche’s emicizumab (ACE-910), that don’t exploit a replacement strategy, but target various effectors of the coagulation cascade. These two drugs are anticipated to encourage a paradigm shift in the treatment of hemophilia.
Topical research study “PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2026” drawn up by GlobalData offers a detailed analysis of the world’s hemophilia market landscape and dynamics. It provides relevant info on the disease etiology, epidemiology, pathophysiology, diagnosis, symptoms and management; reviews the existing and emerging treatment options, uncovers updated statistics on hemophilia therapeutics market revenues, cost of therapy per patient and treatment usage patterns across 9 patient segments and 2 treatment strategies (prophylactic and episodic treatment), and also presents forecasts up to 2026. Moreover, this publication gives strategic competitor assessment, identifies the existing unmet needs in the hemophilia market, provides clinical trial mapping, and also reviews the major forces responsible for the overall market growth and development. A detailed hemophilia therapeutics pipeline analysis is provided in this report. In addition, the report comprises a future outlook for the hemophilia market up to 2026.
Many other in-demand research reports by GlobalData are available in the publisher’s online catalogue at MarketPublishers.com.